CA2874988C - Phenylalkyl sulfamate compound and muscle relaxant composition comprising the same - Google Patents
Phenylalkyl sulfamate compound and muscle relaxant composition comprising the same Download PDFInfo
- Publication number
- CA2874988C CA2874988C CA2874988A CA2874988A CA2874988C CA 2874988 C CA2874988 C CA 2874988C CA 2874988 A CA2874988 A CA 2874988A CA 2874988 A CA2874988 A CA 2874988A CA 2874988 C CA2874988 C CA 2874988C
- Authority
- CA
- Canada
- Prior art keywords
- preparation example
- dioxolan
- methyl
- dioxaspiro
- sulfamate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/72—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D317/34—Oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261660064P | 2012-06-15 | 2012-06-15 | |
| US61/660,064 | 2012-06-15 | ||
| PCT/KR2013/005279 WO2013187727A1 (en) | 2012-06-15 | 2013-06-14 | Phenylalkyl sulfamate compound and muscle relaxant composition comprising the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2874988A1 CA2874988A1 (en) | 2013-12-19 |
| CA2874988C true CA2874988C (en) | 2016-05-24 |
Family
ID=49758484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2874988A Active CA2874988C (en) | 2012-06-15 | 2013-06-14 | Phenylalkyl sulfamate compound and muscle relaxant composition comprising the same |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9221783B2 (https=) |
| EP (1) | EP2861571B1 (https=) |
| JP (1) | JP6001168B2 (https=) |
| KR (1) | KR101699145B1 (https=) |
| CN (1) | CN104428292B (https=) |
| BR (1) | BR112014031396B1 (https=) |
| CA (1) | CA2874988C (https=) |
| ES (1) | ES2635067T3 (https=) |
| WO (1) | WO2013187727A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3443959A1 (en) * | 2013-12-12 | 2019-02-20 | Bio-Pharm Solutions Co., Ltd. | Sulfamate derivative compounds for use in treating or alleviating pain |
| US10081615B2 (en) | 2013-12-12 | 2018-09-25 | Bio-Pharm Solutions Co., Ltd. | Sulfamate derivative compounds for use in treating or alleviating pain |
| KR101792999B1 (ko) * | 2013-12-12 | 2017-11-02 | (주)바이오팜솔루션즈 | 간질 예방 또는 치료용 설파메이트 유도체 화합물 |
| KR20230051206A (ko) * | 2020-09-10 | 2023-04-17 | (주)바이오팜솔루션즈 | 정신질환 치료 또는 완화용 설파메이트 유도체 화합물 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US459160A (en) * | 1891-09-08 | Half to isaac l | ||
| US2884444A (en) | 1956-01-13 | 1959-04-28 | Carter Prod Inc | 2-phenyl-1,3 propane diol dicarbamate |
| US2937119A (en) | 1959-06-11 | 1960-05-17 | Carter Prod Inc | Nu-monosubstituted-2, 2-dialkyl-1, 3-propanediol dicarbamates |
| US3313692A (en) | 1958-04-21 | 1967-04-11 | Armour Pharma | Method of inducing calming and muscle relaxation with carbamates |
| US3265727A (en) | 1962-06-26 | 1966-08-09 | Armour Pharma | Phenyl alkyl-1, 2 dicarbamates |
| US4591601A (en) | 1985-04-12 | 1986-05-27 | Mcneilab, Inc. | Anticonvulsant dioxolane methane sulfamates |
| US4792569A (en) | 1987-08-27 | 1988-12-20 | Mcneilab, Inc. | Anticonvulsant phenethyl sulfamates |
| US5025031A (en) | 1989-11-30 | 1991-06-18 | A. H. Robins Co., Inc. | Aryl and aryloxyalkyl sulfamate esters useful as anticonvulsants |
| JPH05140144A (ja) * | 1991-11-14 | 1993-06-08 | Nitto Denko Corp | 新規なアルコール及びその製法、及び新規なエステル並びにこの新規なアルコールからニンジン類の発根誘起物質を製造する方法 |
| JPH07228549A (ja) * | 1994-02-17 | 1995-08-29 | Japan Tobacco Inc | 新規な４−アリール−２，３−ジヒドロキシ酪酸誘導体及びその製造方法 |
| US6436953B1 (en) * | 1998-09-23 | 2002-08-20 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Tetrahydropyridoethers |
| IS7839A (is) * | 2002-11-22 | 2004-05-23 | Merck Frosst Canada Ltd. | 4-oxó-1-(3-setið fenýl-1,4-díhýdró-1,8-naftýridín-3-karboxamíð fosfódíesterasa-4 hindrar |
| US20050192286A1 (en) * | 2003-10-22 | 2005-09-01 | Neurocrine Biosciences, Inc. | Ligands of melanocortin receptors and compositions and methods related thereto |
| WO2007005935A2 (en) * | 2005-07-06 | 2007-01-11 | Molecular Neuroimaging, Llc | Norepinephrine transporter radiotracers and methods of syntheses thereof |
| BRPI0617687A2 (pt) * | 2005-10-25 | 2011-08-02 | Ludwig Inst Cancer Res | composto, método para proteger um indivìduo mamìfero contra, ou tratar, um vìrus, infecção microbiana, parasita, uma doença auto-imune, cáncer, alergia ou asma, e, composição farmacêutica |
-
2013
- 2013-06-14 JP JP2015517189A patent/JP6001168B2/ja active Active
- 2013-06-14 EP EP13803704.9A patent/EP2861571B1/en active Active
- 2013-06-14 KR KR1020147035195A patent/KR101699145B1/ko active Active
- 2013-06-14 BR BR112014031396A patent/BR112014031396B1/pt active IP Right Grant
- 2013-06-14 WO PCT/KR2013/005279 patent/WO2013187727A1/en not_active Ceased
- 2013-06-14 US US14/401,990 patent/US9221783B2/en active Active
- 2013-06-14 ES ES13803704.9T patent/ES2635067T3/es active Active
- 2013-06-14 CN CN201380031295.2A patent/CN104428292B/zh active Active
- 2013-06-14 CA CA2874988A patent/CA2874988C/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN104428292A (zh) | 2015-03-18 |
| KR101699145B1 (ko) | 2017-02-03 |
| CA2874988A1 (en) | 2013-12-19 |
| CN104428292B (zh) | 2017-02-08 |
| JP2015531746A (ja) | 2015-11-05 |
| EP2861571A4 (en) | 2015-11-04 |
| JP6001168B2 (ja) | 2016-10-05 |
| ES2635067T3 (es) | 2017-10-02 |
| EP2861571B1 (en) | 2017-05-03 |
| BR112014031396A2 (pt) | 2017-06-27 |
| EP2861571A1 (en) | 2015-04-22 |
| BR112014031396B1 (pt) | 2019-11-26 |
| US9221783B2 (en) | 2015-12-29 |
| WO2013187727A1 (en) | 2013-12-19 |
| US20150266848A1 (en) | 2015-09-24 |
| KR20150023393A (ko) | 2015-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2710902T3 (es) | Compuesto derivado de carbamatos de fenilalquilo y composición farmacéutica que contiene el mismo | |
| TW202313544A (zh) | 間苯二酚、其製造方法及其用途 | |
| CA2874988C (en) | Phenylalkyl sulfamate compound and muscle relaxant composition comprising the same | |
| JP5838226B2 (ja) | フェニルカルバメート誘導体の製造方法 | |
| CN109071418A (zh) | 氨基酸衍生物的前药 | |
| JP6220975B2 (ja) | 痛症を治療又は緩和するためのスルファメート誘導体化合物。｛ｓｕｌｆａｍａｔｅ ｄｅｒｉｖａｔｉｖｅ ｃｏｍｐｏｕｎｄｓ ｆｏｒ ｕｓｅ ｉｎ ｔｒｅａｔｉｎｇ ｏｒ ａｌｌｅｖｉａｔｉｎｇ ｐａｉｎ｝ | |
| US20050256322A1 (en) | Production method of hexahydrofurofuranol derivative, intermediate therefor and production method thereof | |
| JP6335307B2 (ja) | てんかん予防または治療用スルファメート誘導体化合物 | |
| JP7648746B2 (ja) | 精神疾患の治療又は軽減のためのスルファメート誘導体化合物 | |
| CN100537575C (zh) | 六氢呋喃并呋喃醇衍生物的制备方法、其中间体及其制备方法 | |
| JP2004107315A (ja) | ヘキサヒドロフロフラノール誘導体の製造方法、その中間体およびその製造方法 | |
| CN119365476A (zh) | 一种环戊基腺苷衍生物及其药物用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20141127 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251009 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - SMALL Year of fee payment: 12 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251104 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251104 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260224 |